Rockwell Medical (NASDAQ:RMTI) Upgraded at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Rockwell Medical (NASDAQ:RMTI) to a strong-buy rating in a research note published on Thursday morning,Zacks.com reports.

RMTI has been the subject of several other reports. Rodman & Renshaw initiated coverage on shares of Rockwell Medical in a report on Thursday. They set a “buy” rating and a $5.00 target price for the company. StockNews.com upgraded shares of Rockwell Medical from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Rockwell Medical in a research note on Wednesday, September 11th.

Rockwell Medical Price Performance

Rockwell Medical stock opened at $2.36 on Thursday. The company has a quick ratio of 1.60, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. Rockwell Medical has a one year low of $1.16 and a one year high of $5.15. The business has a fifty day moving average price of $3.68 and a 200-day moving average price of $2.61.

Institutional Trading of Rockwell Medical

Several hedge funds have recently made changes to their positions in the company. Concurrent Investment Advisors LLC purchased a new position in Rockwell Medical during the 3rd quarter valued at about $40,000. Verus Capital Partners LLC purchased a new stake in Rockwell Medical in the third quarter valued at approximately $51,000. Barclays PLC acquired a new position in Rockwell Medical during the third quarter valued at approximately $90,000. Beacon Financial Advisory LLC acquired a new position in shares of Rockwell Medical during the third quarter worth $98,000. Finally, XTX Topco Ltd raised its holdings in Rockwell Medical by 45.7% in the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock valued at $113,000 after acquiring an additional 8,922 shares in the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.